Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1–infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275)

Daniel E. Nixon,Ronald J. Bosch,Ellen S. Chan,Nicholas T. Funderburg,Sally Hodder,Jordan E. Lake,Michael M. Lederman,Karin L. Klingman,Judith A. Aberg, Katherine Bergstrom,Linda Boone,Laurie Myers, Debra Meres,Katherine Shin,Francesca Aweeka,Karen Cavanagh,Kathleen A. Medvik,Laura Hovind,Karl Shaw, Amanda Zadzilla

Journal of Clinical Lipidology（2017）

引用 30|浏览31

暂无评分

摘要

•Atorvastatin for 20 weeks was studied in 98 individuals with suppressed HIV infection.•Atorvastatin did not decrease biomarkers of immune activation and inflammation.•Atorvastatin treatment resulted in robust reductions LDL-C, oxLDL, and LpPLA2.•Atorvastatin was well tolerated with no significant toxicity over 20 weeks.

查看译文

关键词

HIV,Statin,Immune activation,Inflammation,Oxidized LDL,Cardiovascular

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要